Nifty struggles below 10,300; L&T top gainer, Aurobindo dips 3%

Epic Update Aurobindo PharmaEpic Update Aurobindo Pharma

Equity benchmarks remained under pressure amid consolidation, tracking subdued global cues. Investors await outcome of GST Council meet and SBI earnings later today.

The 30-share BSE Sensex was down 58.78 points at 33,192.15 and the 50-share NSE Nifty fell 19.60 points to 10,289.40.

Drug firm Aurobindo Pharma today reported a 28.96 percent rise in its consolidated net profit to Rs 780.97 crore for the September quarter of the current fiscal mainly on account of robust sales in the US and European Union.

For more information ✆ – 0731-6642300 or Visit http://www.epicresearch.co

Facebook Twitter YouTube Pinterest Linkedin Google+

You may also like:

Sensex, Nifty rangebound; RBI’s MPC meet outcome awaited' width= Sensex, Nifty continue to be sluggish ahead of RBI policy; Europe mixed' width=
Sensex, Nifty rangebound; RBI’s MPC meet outcome awaited Sensex, Nifty continue to be sluggish ahead of RBI policy; Europe mixed
Share Button

About the Author

Epic Research
Epic Research
Epic Research - Investment Adviser is a leading financial services provider with presence in Indian and other global capital markets. Call on - 0731-664-2300